Drugs in Clinical Development for Chronic Obstructive Pulmonary Disease

August 2011
Pharmaceutical Medicine - New Zealand;2011, Vol. 25 Issue 4, p251
Academic Journal
The article discusses advances in the pharmacotherapy of chronic obstructive pulmonary disease (COPD). It cites bronchitis, emphysema and mucus hypersecretion as conditions underlying COPD. Treatment options for suppressing pulmonary inflammation in COPD are roflumilast and protease inhibition. Also included are information on obstacles to effective drug development in COPD and agents currently in clinical development for COPD management.


Related Articles

  • Rehabilitation for COPD patients. Kearney, Sarah // Independent Nurse;2/1/2010, p40 

    The article focuses on the importance of pulmonary rehabilitation to patients suffering from chronic obstructive pulmonary disease (COPD). COPD refers to the condition that is commonly experienced by people who experience airflow obstruction after they have been diagnosed with emphysema or...

  • Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Samyshkin, Yevgeniy; Kotchie, Robert; Mörk, Ann-Christin; Briggs, Andrew; Bateman, Eric // European Journal of Health Economics;Jan2014, Vol. 15 Issue 1, p69 

    Objective: To estimate the cost-effectiveness of adding a selective phosphodiesterase-4 inhibitor, roflumilast, to a long-acting bronchodilator therapy (LABA) for the treatment of patients with severe-to-very severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis...

  • Surgical approaches for lung volume reduction in emphysema. CRAWFORD, EMMA; SRINIVASAN, KOOTTALAI; MOUDGIL, HARMESH; NAICKER, THIRUMALAIRENGARAJAN; AHMAD, NAWAID // Clinical Medicine;Oct2014, Vol. 14 Issue 5, p558 

    A letter to the editor is presented in response to the article related to lung volume reduction surgery (LVRS) by S. J. Clark and others in the December 10, 2013 issue.

  • RESPIRATORY TRACT.  // Nurse Practitioners Prescribing Reference;Winter2009/2010, Vol. 16 Issue 4, p257 

    The article offers information on prescriptions of various drugs to treat respiratory tract disorders. Advair Diskus from GlaxoSmithKline is used to maintain treatment of asthma in patients who are not adequately controlled on other asthma-controller medications. Combivent from Boehringer...

  • Helping the Chronically Short of Breath. Roper, Jenevieve; Kravitz, Len // IDEA Fitness Journal;Jun2013, Vol. 10 Issue 6, p20 

    The article focuses on the new way of exercise that helps people with emphysema, chronic bronchitis and other ailments that is caused due to chronic obstructive pulmonary disease (COPD). It mentions that people with COPD have trouble in exercising still they should be encouraged to carry out...

  • Fluticasone and Vilanterol Oral Inhalation.  // AHFS Consumer Medication Information;Apr2019, p1 

    The combination of fluticasone and vilanterol is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary (COPD; a group of diseases that affect the lungs and airways, that includes chronic bronchitis and emphysema). Fluticasone is in a...

  • Roflumilast Tablets (Daliresp®). Elliott, William T.; Chan, James // Internal Medicine Alert;4/29/2011, Vol. 33 Issue 8, p62 

    The article offers information on the drug Roflumilast, an oral phosphodiesterase 4 (PDE4) inhibitor used to treat chronic osbtructive pulmonary disease (COPD), with its brand name Daliresp from Forest Pharmaceuticals Inc.

  • Roflumilast (Daliresp) for Chronic Obstructive Pulmonary Disease. BAZALDUA, ORALIA V.; DAVIDSON, DEWAYNE A.; BABB, FRANKLYN C. // American Family Physician;2/15/2014, Vol. 89 Issue 4, p300 

    This article evaluates the oral selective phosphodiesterase-4 inhibitor Roflumilast (Daliresp) for chronic obstructive pulmonary disease (COPD).

  • Chronic obstructive pulmonary disease: insidious, debilitating and costly. Chapman, John // Australian Journal of Pharmacy;May2013, Vol. 94 Issue 1116, p78 

    The article discusses the pathophysiology, symptoms and treatment of chronic obstructive pulmonary disease (COPD). It mentions the differences between emphysema and chronic bronchitis, the risk factors of developing COPD including cigarette smoking, air pollution and impaired lung growth and a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics